Caribou Biosciences Shares Plunge 40% Following Announcement to Halt CAR-T Program
CRBU Caribou Biosciences Inc
$1.13 -4.62%
View chart & analysis → - 1Caribou Biosciences will discontinue further development of vispa-cel and CB-011.
- 2Caribou Biosciences shares fell 40% in Tuesday after-hours trading.
- 3As of June 30, 2026, Caribou held $113.8 million in cash, cash equivalents, and marketable securities.
So what's the key point?
Caribou Biosciences decided to stop developing its current treatments. Following this news, the company's stock price dropped by 40%.
Source Investing.com +4 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.